Avapag 20 mg Tablet

Brand Name: Avapag

Molecule: Avatrombopag

Strength: 20 mg

Quantity: 28 Tablets

Form: Tablet

Packaging Type: Bottle

Manufacturer/Marketed By: Everest Pharma

Country of Origin: Bangladesh

Description

Avapag 20 mg Tablet contains Avatrombopag, a thrombopoietin receptor agonist used to increase platelet counts in patients with chronic liver disease or chronic immune thrombocytopenia (ITP). It helps reduce bleeding risk before medical or dental procedures.

Benefits

Helps increase platelet count safely
Lowers risk of bleeding complications
Reduces need for platelet transfusion
Convenient oral once-daily dosing
Effective alternative when other treatments fail

Indications and Usage

Avapag 20 mg Tablet is indicated for:

Thrombocytopenia in chronic liver disease before scheduled procedures
Chronic immune thrombocytopenia (ITP) in adults with low platelet count despite prior therapy

Not for emergency bleeding management.

How it Works

Avatrombopag activates the thrombopoietin (TPO) receptors in bone marrow, stimulating platelet production and increasing circulating platelet levels to reduce bleeding risk.

Dosage & Administration

Dose depends on indication, platelet count & physician assessment
Usually taken once daily with food, for the prescribed duration
Swallow tablets whole with water
Do not take extra doses if a dose is missed
Requires routine platelet monitoring

Never start, adjust, or stop treatment without medical advice.

Side Effects

Common side effects:

Headache
Fatigue
Nausea
Fever
Abdominal discomfort

Serious side effects (seek urgent care):

Blood clots
Severe shortness of breath or chest pain
Liver function abnormalities
Severe headache or neurological symptoms

Warning and Precaution

Not recommended during pregnancy or breastfeeding unless advised
Use cautiously in patients with history of blood clots or cardiovascular disease
Regular liver and platelet monitoring required
Inform doctor about ongoing medications, especially anticoagulants
Do not use to normalize platelet count beyond target range — risk of thrombosis